R. Hutabarat

发表

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

N. Svrzikapa, G. Shapiro, P. LoRusso, 2013, Cancer discovery.

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.

Amy Chan, Akin Akinc, Stuart Milstein, 2014, Journal of the American Chemical Society.

Discovery and development of therapeutic aptamers.

K. Thompson, R. Hutabarat, P. Bouchard, 2010, Annual review of pharmacology and toxicology.

Isolation identification and partial characterization of proteases in Carica papaya L. callus

R. Hutabarat, 1985 .

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.

K. G. Rajeev, M. Manoharan, A. Akinc, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

B. Jilma, P. Knöbl, R. Hutabarat, 2010, Thrombosis and Haemostasis.

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

S. Milstein, K. G. Rajeev, M. Manoharan, 2015, Nature Medicine.

Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura

B. Jilma, P. Knöbl, R. Hutabarat, 2009, Transfusion.

In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR)

N. Svrzikapa, B. Bettencourt, A. Akinc, 2010, Silence.

First-inHuman Evaluation of Anti – von Willebrand Factor Therapeutic Aptamer ARC 1779 in Healthy Volunteers

J. M. Healy, R. Schaub, R. Hutabarat, 2007 .

Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia

J. Ritter, L. Nechev, K. Fitzgerald, 2012, Arteriosclerosis, Thrombosis, and Vascular Biology.

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.

B. Bettencourt, Tracy S. Zimmermann, J. Gollob, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

K. G. Rajeev, M. Manoharan, A. Akinc, 2017, Nucleic acids research.

A status report on RNAi therapeutics

John Maraganore, J. Gollob, J. Maraganore, 2010, Silence.

Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

B. Bettencourt, P. Lozeron, P. Hawkins, 2013, The New England journal of medicine.

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

A. Strahs, A. Akinc, B. Sørensen, 2014 .

Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways.

K. G. Rajeev, M. Manoharan, M. Egli, 2023, Journal of medicinal chemistry.

Cytokine traps: multi-component, high-affinity blockers of cytokine action

Scott Carver, G. Yancopoulos, N. Stahl, 2003, Nature Medicine.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

B. Bettencourt, Svetlana Shulga-Morskaya, J. Gollob, 2014, The Lancet.

Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779

D. Wagner, J. Tanguay, R. Schaub, 2009, Journal of thrombosis and haemostasis : JTH.

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

R. Schaub, B. Jilma, R. Hutabarat, 2008 .

First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers

J. M. Healy, R. Schaub, R. Hutabarat, 2007, Circulation.

ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis

P. Lozeron, L. Nechev, P. Hawkins, 2011 .

Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles

Svetlana Shulga Morskaya, G. Wang, M. Stoffel, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Abstract 11936: Development of Monthly to Quarterly Subcutaneous Administration of RNAi Therapeutics Targeting the Metabolic Diseases Genes PCSK9, ApoC3 and ANGPTL3

S. Milstein, K. Charissé, J. Horton, 2014 .

Purification and characterization of an ethanol-induced UDP-glucuronosyltransferase.

R. Hutabarat, G. Yost, 1989, Archives of biochemistry and biophysics.

ReviewA status report on RNAi therapeutics

J. Gollob, J. Maraganore, C. Gamba-Vitalo, 2015 .

Reviewreport on RNAi therapeutics

J. Gollob, J. Maraganore, C. Gamba-Vitalo, 2010 .

Disposition of drugs in cystic fibrosis. III. Acetaminophen

A. Smith, Arnold L. Smith, J. Unadkat, 1991, Clinical pharmacology and therapeutics.

Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim

B. Ramsey, S. Mcnamara, Arnold L. Smith, 1991, Clinical pharmacology and therapeutics.

Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: In vitro‐in vivo correlation and characterization of its kinetics of acetylation in lymphocytes

Arnold L. Smith, J. Unadkat, R. Hutabarat, 1994, Clinical pharmacology and therapeutics.

DISCOVERY OF A POTENT, DIRECT THROMBIN INHIBITING APTAMER

Paul J. Hatala, Scott D. Lewis, Ryan M. Boomer, 2007 .

Abstract 7: A Subcutaneous, Potent and Durable RNAi Platform Targeting Metabolic Diseases, Genes PCSK9, ApoC3 and ANGPLT3

S. Milstein, K. Charissé, J. Horton, 2014 .

In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR)

R. Meyers, R. Hutabarat, S. Kuchimanchi, 2010, Silence.

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.

B. Bettencourt, Tracy S. Zimmermann, J. Gollob, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.